Zero ad trackers.We never sell your data.Healthcare professional?Clinician Resources
Home/Rare Diseases/Retinitis Pigmentosa

Eye & Vision

Retinitis Pigmentosa (RP) Clinical Trials and Treatments

Also called RP, retinal dystrophy

Retinitis pigmentosa (RP) is a group of inherited retinal dystrophies characterized by progressive degeneration of photoreceptor cells, particularly affecting rod cells initially with secondary cone involvement developing later in disease course. The disease follows various inheritance patterns including autosomal recessive, autosomal dominant, and X-linked, with more than 130 genes now known to cause RP.

In plain words, retinitis pigmentosa is a group of inherited eye conditions where the light-sensing cells at the back of the eye slowly break down. Seeing in dim light gets hard first, then side vision narrows over the years.

Get an email when new Retinitis Pigmentosa trials open or the FDA decides. Get alerts

Retinitis Pigmentosa

Where treatments stand, from ClinicalTrials.gov and FDA labels

FDA review1

Mogenry, First half of 2027

FDA-approved medicines1

Luxturna

Retinitis Pigmentosa has 1 FDA-approved medicine, 59 open or active clinical trials, and a pending FDA decision on Mogenry, due First half of 2027.

Labels checked October 21, 2026. Corticosteroids and immune globulins count once each.Download the data

Latest for Retinitis Pigmentosa

See all trialsThe week in rare disease

Each date is the day a change was posted. Open an item to see where things stand now.

More about Retinitis Pigmentosa

Patients typically first notice night blindness and difficulty adapting to darkness, as rod photoreceptors (responsible for dim light vision) are preferentially affected early. This is followed by progressive loss of peripheral vision creating the characteristic tunnel vision phenotype as disease advances centrally over years to decades. On ophthalmologic examination, characteristic bone-spicule-shaped pigmentary changes appear in the retina, along with optic disc pallor and vascular attenuation as hallmark findings.

Keep reading about Retinitis Pigmentosa

Electroretinography confirms progressive photoreceptor dysfunction with reduced or extinguished responses. With progression, most patients develop significant central vision loss by late adulthood, though progression rates vary considerably. Genetic heterogeneity means different mutations cause varying clinical presentations, progression rates, and extraocular manifestations. Some patients retain useful vision into late life while others progress more rapidly.

What are the symptoms of Retinitis Pigmentosa?

These are common symptoms of Retinitis Pigmentosa, and how strong they are varies from person to person.

  • Night blindness and difficulty seeing in dim light
  • Progressive peripheral vision loss
  • Tunnel vision in later stages
  • Difficulty adapting to light changes
  • Floaters and dark spots in vision
  • Gradual central vision loss

Who gets Retinitis Pigmentosa?

Retinitis pigmentosa typically manifests in childhood or early adulthood, though age of onset varies considerably from infancy to later adult years depending on genetic subtype.

The condition affects males and females equally in autosomal recessive and dominant forms, though X-linked forms predominantly affect males while females serve as carriers. All ethnic backgrounds are affected, with different genetic subtypes varying in frequency across populations. Some subtypes show higher prevalence in specific geographic regions or populations. Age of symptom onset, progression rate, and clinical severity vary depending on the specific causative gene mutation.

Next steps: find trials you might fitsee approved treatmentsget help payingget alerts

Which medicines are FDA-approved for Retinitis Pigmentosa?

There is currently 1 FDA-approved medication for Retinitis Pigmentosa.

voretigene neparvovec-rzyl
Spark Therapeutics (Roche); distributed in the US by Genentech
Search

Source: openFDA drug labeling data. This list may not include all treatments. Always consult your doctor.

Which new Retinitis Pigmentosa medicines are in trials?

Investigational medicines Trial Friend tracks for Retinitis Pigmentosa, with trial results, safety findings and where each one stands.

How to get help paying for Retinitis Pigmentosa treatment

Charity funds and drugmaker programs for Retinitis Pigmentosa, checked at the source.

Which insurance do you have? Pick one to see what fits. Tap it again to clear.
Your insurance
Charity funds

No charity fund for this condition is open right now. Funds reopen when they receive new donations; the foundations let you sign up to be told when one opens.

Status as each foundation showed it on November 16, 2026.
Drugmaker programs
Open a medicine for who qualifies, by insurance type.

Every program and fund for Retinitis Pigmentosa, by insurance →

Side effects people have reported to the FDA

Side effects people have reported to the FDA

Real-world side effect reports from the FDA Adverse Event Reporting System (FAERS). Includes both FDA-approved drugs and investigational therapies from active clinical trials. Click any drug to see what patients reported.

Loading side effect data...

Diagnosis and genetic testing

Genetic testing for Retinitis Pigmentosa

Genetic testing can confirm a diagnosis, guide treatment decisions, and identify family members who may be at risk.

Finding labs...

Trusted Retinitis Pigmentosa resources

Reputable organizations and medical references for learning more about Retinitis Pigmentosa, including disease registries, foundation resources, and clinical guidelines.

Active clinical trials for Retinitis Pigmentosa

Use this Retinitis Pigmentosa clinical trial finder to see the 27 studies recruiting patients and 3 not yet recruiting in the United States and worldwide, with eligibility criteria in plain English. Of these, 16 test a treatment and 14 are observational studies or registries; each card says which. Every trial comes from ClinicalTrials.gov.

FDA decision ahead: Mogenry (sonpiretigene isteparvovec, MCO-010) in the first half of 2027. All upcoming decisions

Jump to the trial list, the site map, the pipeline timeline or the medication checker.

Note: Trial recruitment statuses on ClinicalTrials.gov may not immediately reflect recent FDA decisions, sponsor announcements, or enrollment changes. Always confirm a trial's current status directly with the study coordinator before making plans.

59 active trials worldwide
Filter:
Sort:
Not yet recruitingObservational study, no treatment givenRecently updatedNCT07941544

Njinsky Ambispective Cellular Product Safety and Outcomes Registry

Intervention: Umbilical Cord Mesenchymal Stem Cells, Stromal Vascular fraction

Sponsor: Njinsky Medical Centre

This ambispective observational registry will describe safety events, treatment patterns, and disease-specific clinical assessments among patients receiving cultured umbilical cord mesenchymal stromal cells (UCMSCs), autologous uncultured stromal vascular fraction (SVF), or both ...

Ages not specified1 location
Expected to start Dec 2026Updated yesterdayEst. Dec 2030 (~4y 1m)
Not yet recruitingTreatment trialPhase 2Recently updatedNCT07943312

GA001 Injection in Retinitis Pigmentosa

Intervention: GA001, Sham injection

Sponsor: GenAns Biotechnology Co., Ltd

This Phase II clinical trial evaluates the safety, tolerability, and efficacy of GA001 Injection in patients with retinitis pigmentosa.

Ages 18 Years to 70 Years1 location
Expected to start Apr 2027Updated yesterdayEst. Nov 2029 (~3 years)
RecruitingObservational study, no treatment givenRecently updatedNCT07228793

Natural History Study of Patients With EYS-Associated RP

Intervention: Whole exome/genome sequencing

Sponsor: Sensor Technology for Deafblind

This natural history study of patients with EYS mutations from Russia and former CIS (Commonwealth of Independent States) territories will accelerate the development of outcome measures for clinical trials. Sensitive, reliable outcome measures of retinal degeneration will greatly...

Ages 14 Years to 100 Years1 location
Started Nov 2025Updated 2 days agoEst. Dec 2029 (~3 years)
RecruitingObservational study, no treatment givenRecently updatedNCT02617966

Rod and Cone Mediated Function in Retinal Disease

Sponsor: National Eye Institute (NEI)

Background:

Ages 5 Years to 100 Years1 location
Started Mar 2016Updated 6 days agoEst. Dec 2029 (~3y 1m)
RecruitingTreatment trialPhase 1/2Recently updatedNCT06242379

Safety and Efficacy of Stem Cell Small Extracellular Vesicles in Patients With Retinitis Pigmentosa

Intervention: GMP compliant-BM-MSC derived sEVs

Sponsor: Mahidol University

The aim of this clinical trials is to evaluate the safety and efficacy of intravitreal injection of GMP-compliant BM-MSC-derived sEVs in patients with retinitis pigmentosa.

Ages 18 Years+1 location
Started May 2024Updated 6 days agoEst. May 2027 (~6 months)
Find Retinitis Pigmentosa trials near you, ranked by distance →
Active trial locations42 cities in the US
A study site. Select it to see its trials and get directions. Several sites close together. Select the number to zoom in.
+34 more

Trial Pipeline

Jan 2021 to Nov 2031
2021
2023
2025
2027
2029
2031
now
Early Phase 1
Phase 1
Phase 2
Phase 3
Observational
Observational
RecruitingNot yet recruitingDelayed startTodayHover a bar for trial details

Read more about Retinitis Pigmentosa trials

Need help understanding these trials?
Answers with sources, in plain English
Start withor ask
Run a Retinitis Pigmentosa foundation or patient group?
You can put this live trial list on your own website. It updates itself, and it's free.
Get the embed code →

Data from ClinicalTrials.gov, U.S. National Library of Medicine.
Always talk to your doctor before considering a clinical trial.

Retinitis Pigmentosa patient communities

Facebook groups, Reddit communities and YouTube channels where Retinitis Pigmentosa patients, caregivers and advocacy groups talk.

Retinitis Pigmentosa news and guides

Trial Friend articles about Retinitis Pigmentosa, newest first

Companies developing Retinitis Pigmentosa treatments

Drugmakers that list Retinitis Pigmentosa in their rare disease portfolio, 3 in all.

Questions people ask about Retinitis Pigmentosa